Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

More Than 200 New Genes Discovered

12.08.2004


Finnish company Jurilab has announced the completion of a genome-wide scan in Acute Myocardial Infarction in the East Finland Founder Population. The study gives invaluable insight into the interplay of different genes and pathways leading to coronary disease. The study has re-affirmed the majority of genes previously known to be associated with AMI. The new genes discovered include also ones, which appear to give humans a strong protection against coronary disease.

"These discoveries open up a new chapter in the development of predictive tests and much improved therapeutics for coronary heart disease", said Professor Jukka T. Salonen, Jurilab’s chief scientific officer, and "The successful AMI GWS constitutes a proof-of-concept for Jurilab’s fast and inexpensive gene discovery approach. We are in the process of carrying out similar studies in our main focus areas of cardiovascular and metabolic diseases".

DNA samples collected from homogenous Eastern Finland



The DNA samples used in the study were collected in the 1980’s from a genetically-homogenous population that can be accurately traced back to a few hundred founders in the 1600’s. In the study, coronary events recorded prospectively during almost 20 years in families with several members having coronary disease, were compared with extremely healthy controls.

The prospective study design is invaluable in that it eliminates a bias, which is commonly present in conventional case-control studies. The Jurilab gene discovery team typed over 100,000 single-nucleotide-polymorphisms covering the majority of structural blocks in the genome of Eastern Finns, who share exceptionally large genomic regions. Jurilab’s proprietary data-mining software was used in the statistical analysis.

The study was supported by Tekes (National Technology Agency of Finland) and carried out in collaboration with the University of Kuopio. Jurilab participated in Tekes’ Diagnostics 2000 Technology Programme. Technology programme focused on clinical diagnostics and its budget was EUR 33 million.

Mira Banerjee | alfa
Further information:
http://www.tekes.fi

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NASA's AIM observes early noctilucent ice clouds over Antarctica

05.12.2016 | Earth Sciences

Shape matters when light meets atom

05.12.2016 | Physics and Astronomy

Researchers uncover protein-based “cancer signature”

05.12.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>